Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SZC for rapid correction of pre-transplant hyperkalemia in CKD stage 5
ChiCTR2300072940Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia and chronic kidney disease (CKD), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Serum potassium. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2300072940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072940.